While, in theory, a combined inhibitor of Dyrk1 and CBS in DS may be an attractive approach — given that both of these enzymes play important, and mostly non-overlapping pathogenetic mechanisms in DS — the potential utility EGCG-based approaches in a clinical DS setting remains to be further elucidated. Here, CBS is linked to Dravet syndrome.